• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is BeOne Medicines (ONC) A Bargain After Its TEVIMBRA Reimbursement Milestone?

    Simply Wall St·10/08/2026 10:34:03
    Listen to the news

    Why BeOne Medicines Matters After Its Latest Canadian Milestone

    BeOne Medicines (ONC) has finished key reimbursement talks with the pan-Canadian Pharmaceutical Alliance for TEVIMBRA in first-line nasopharyngeal carcinoma. That decision moves the therapy closer to publicly funded access for eligible patients.

    The TEVIMBRA milestone arrives while BeOne Medicines trades at US$364.02, with the stock posting a 20.21% 90 day share price return and a 3 year total shareholder return of about 100%. This indicates that longer term momentum remains stronger than the shorter term moves.

    See how BeOne Medicines compares with other cancer-focused players by reviewing the hand picked 35 healthcare AI stocks that are already drawing attention from investors.

    Recent gains at BeOne Medicines could point to investors reassessing the underlying oncology portfolio, rather than just riding headline excitement around TEVIMBRA. How far does the current share price already reflect that story?

    Most Popular Narrative: 16% Undervalued

    Analyst modelling pegs BeOne Medicines at a fair value of about $433, compared with the recent $364.02 close, which frames the current price as a discount while still leaving execution as the swing factor.

    BeOne's strong revenue growth (41% YoY in Q2; updated full-year guidance of $5 to $5.3B) is underpinned by rapid demand expansion for differentiated, best-in-class oncology therapies like BRUKINSA, supported by a growing, aging population and increased global healthcare spending, both of which point to a sustainably expanding addressable market and future revenue growth.

    See why 20 investors see BeOne Medicines as 16% undervalued.

    Result: Fair Value of $433.02 (UNDERVALUED)

    Still, the bullish BeOne Medicines story runs into two clear pressure points: heavy reliance on BRUKINSA and exposure to tougher drug pricing or reimbursement decisions.

    Find out about the key risks to this BeOne Medicines narrative.

    Another Angle On BeOne Medicines’ Valuation

    The earlier fair value work presents BeOne Medicines as undervalued at $364.02, yet the current P/E of 63.1x suggests a different perspective. That figure is well above the US Biotechs average of 16.9x, the peer group at 27.5x, and even a fair ratio of 34.5x that the market could move toward over time. For investors, that gap can either indicate room for expectations to cool or a premium that continues as long as growth hopes remain, so it is important to be clear about which side of that trade you are assuming.

    See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:ONC P/E Ratio as at Oct 2026
    NasdaqGS:ONC P/E Ratio as at Oct 2026

    Next Steps

    If the BeOne Medicines story so far feels mixed, it may be important for you to review the data yourself and weigh the potential upside against the risks. To see what is driving optimism, review the 3 key rewards

    Looking For More Investment Ideas Beyond BeOne Medicines?

    If BeOne Medicines has sharpened your focus on where capital works hardest, do not stop with a single ticker when a broader watchlist could sharpen your edge.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.